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Novel gene function revealed by mouse
mutagenesis screens for models of age-related
disease
Paul K. Potter1,*, Michael R. Bowl1,*, Prashanthini Jeyarajan1,*, Laura Wisby1, Andrew Blease1,
Michelle E. Goldsworthy1, Michelle M. Simon1, Simon Greenaway1, Vincent Michel2, Alun Barnard3,
Carlos Aguilar1, Thomas Agnew1, Gareth Banks1, Andrew Blake1, Lauren Chessum1, Joanne Dorning1,
Sara Falcone1, Laurence Goosey1, Shelley Harris1, Andy Haynes1, Ines Heise1, Rosie Hillier1, Tertius Hough1,
Angela Hoslin1, Marie Hutchison1, Ruairidh King1, Saumya Kumar1, Heena V. Lad1, Gemma Law1,
Robert E. MacLaren3, Susan Morse1, Thomas Nicol1, Andrew Parker1, Karen Pickford1, Siddharth Sethi1,
Becky Starbuck1, Femke Stelma1, Michael Cheeseman4, Sally H. Cross5, Russell G. Foster6, Ian J. Jackson4,5,
Stuart N. Peirson6, Rajesh V. Thakker7, Tonia Vincent8, Cheryl Scudamore1, Sara Wells1, Aziz El-Amraoui2,
Christine Petit2, Abraham Acevedo-Arozena1, Patrick M. Nolan1, Roger Cox1, Anne-Marie Mallon1
& Steve D.M. Brown1
Determining the genetic bases of age-related disease remains a major challenge requiring a
spectrum of approaches from human and clinical genetics to the utilization of model
organism studies. Here we report a large-scale genetic screen in mice employing a
phenotype-driven discovery platform to identify mutations resulting in age-related disease,
both late-onset and progressive. We have utilized N-ethyl-N-nitrosourea mutagenesis to
generate pedigrees of mutagenized mice that were subject to recurrent screens for mutant
phenotypes as the mice aged. In total, we identify 105 distinct mutant lines from 157
pedigrees analysed, out of which 27 are late-onset phenotypes across a range of physiological
systems. Using whole-genome sequencing we uncover the underlying genes for 44 of these
mutant phenotypes, including 12 late-onset phenotypes. These genes reveal a number of
novel pathways involved with age-related disease. We illustrate our findings by the recovery
and characterization of a novel mouse model of age-related hearing loss.
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T
he increasing incidence and burden of diseases of ageing
highlights the need to identify the genetic determinants
of age-related disease. A wide variety of diseases are
associated with ageing including neurodegenerative disorders,
diabetes, cancer, kidney disease and cardiovascular disease
(reviewed in ref. 1). However, the genetic basis for many of
these diseases remains poorly understood. A proven methodology
to identify novel genes and pathways associated with disease,
which has been employed successfully across a wide range of
physiological systems, is N-ethyl-N-nitrosourea (ENU) -based
phenotype-driven screening2,3. The principle involves inducing
random point mutations throughout the murine genome with
ENU and then screening offspring for phenotypes of interest4.
Mapping and subsequent candidate gene, or more recently whole
genome5,6, sequencing then uncovers the causative mutation.
Phenotype-driven screens have been successful in identifying
novel genes and alleles across a wide range of phenotypic areas4.
In some cases an additional challenge is required to reveal a
phenotype, whereby the effect of the challenge and underlying
mutation combine to result in a phenotype. The success of
this strategy is exemplified by gene function revealed by
immunological challenges7,8.
Age is an important challenge for incorporation in phenotype-
driven screens. Many factors combine to contribute to an ageing
physiology, including mitochondrial dysfunction9 and cellular
senescence10, which may interact with genetic variants to result in
age-related phenotypes. Here we describe our initial findings
from a screen designed to reveal mutations that result in
age-related disease. We have adopted a phenotype-driven,
forward genetic approach utilizing ENU mutagenesis
accompanied by recurrent phenotype screens of aged mutant
mice. This has allowed us to identify phenotypes occurring late in
life resulting from specific ENU-induced mutations. Such
mutants identify genes and pathways that contribute to age-
related disease and allows us to characterize the interactions of
these pathways with an ageing physiology that result specifically
in an age-related phenotype. We demonstrate that this
is a successful approach for identifying mouse mutants with
late-onset phenotypes, and importantly find that these mutant
models reveal a significant number of novel genes and pathways
involved with such diseases.
Results
Pedigree production. We established a large-scale mouse screen
for recessive mutations causing age-related disease incorporating
an ENU mutagenesis4 and phenotype-driven approach. We
screened G3 mice in large pedigrees of up to 100 mice4
(Supplementary Fig. 1a). Briefly, male C57BL/6J mice were
mutagenized with ENU and mated to C3H.Pde6bþ mice11 to
generate G1 founder males. G1 males were subsequently bred to
C3H.Pde6bþ mice to generate G2 offspring. Next, large G3
pedigrees of at around 100 individuals were produced by two
rounds of mating of the founder G1 male to Z8 G2 female
offspring. Large pedigrees ensured sufficient homozygous G3
individuals were available to map a phenotype directly from the
G3 cohort. Each G3 pedigree was generated as two cohorts,
2–3 months apart. Across an entire G3 pedigree comprising some
100 mice, we might expect to identify on average 12 affected
individuals homozygous for an individual recessive mutation
inherited from the G1 founder male. The mixed genetic
background assisted the mapping of mutations underlying the
affected individuals identified in the G3 pedigrees.
Wild-type C3H strains exhibit retinal degeneration, due to a
recessive mutation in the Pde6b gene (Pde6brd1), and hence we
employed the line, C3H.Pde6bþ (ref. 11), congenic for the
BALB/c region encompassing Pde6b and which does not exhibit
retinal degeneration enabling screening for visual abnormalities.
C57BL/6J also carries a recessive mutation in the Cdh23 gene
resulting in age-related hearing loss (Cdh23ahl) (ref. 12).
Therefore, in our protocol G2 female mice were genotyped for
the Cdh23ahl allele and only offspring from G2 females wild-type
for Cdh23 were used for auditory assessment.
Phenotyping pipeline and mutant detection. We developed and
implemented a high-throughput phenotyping pipeline to examine
the G3 mice generated in the ageing screen (Table 1 and
summarized in Supplementary Fig. 1b). This incorporated many
of the established standard operating procedures that have been
utilized in the International Mouse Phenotyping Consortium
(IMPC, www.impc.org) phenotyping pipeline13. The IMPC has
implemented IMPReSS (www.mousephenotype.org/impress),
a database of standardized phenotyping pipelines that
Table 1 | The Harwell Ageing screen phenotyping pipeline.
Test Phenotypic Area Group Age (weeks)
ECG Cardiac All 12
SHIRPA Neurological Females (males) 13, 66
Grip strength Musculoskeletal/neurological All 13, 66
Slit lamp/opthalmoscope Vision All 15, 49, 65, (73)
Optokinetic drum Vision/neurological All 15, 49, 65, (73)
Click box Hearing Non ahl* 14, 26, 39, 50
Auditory brainstem responseþ click stimulus Hearing Non ahl* 14, 39
Echo-MRI Growth/body composition Males (females) 16, 27, 51, 71
DEXA Musculoskeletal/body composition Females (males) 16, 51,
X-ray Musculoskeletal Females (males) 16, 51, 74
Pupillometry Vision/neurobehaviour All 18, 68
Sleep tracking Neurobehaviour Females (males) 18, 68
Clinical chemistry Pathology Females (males) 28, 53, 80
Fasted bleed Diabetes/metabolism Males (females) 17, 28, 52, 80
Fasted insulin Diabetes/metabolism Males (females) 33, 57, 72
IPGTT Diabetes/metabolism Males (females) 33, 57, 72
ECG, electrocardiogram; DEXA, dual energy X-ray analysis; IPGTT, intraperitoneal glucose tolerance test; MRI, magnetic resonance imaging; SHIRPA, SmithKline Beecham, Harwell, Imperial College and
Royal London Hospital phenotype assessment.
A summary and timetable of the core phenotyping tests in the Harwell Ageing Screen, indicating screening time points. In addition to the documented phenotype tests mice are weighed every 3 months
up until the age of 12 months and then monthly from 12 months onwards. For the tests where a single sex was initially tested the other sex was screened when outliers were suspected. The screening
timetable is flexible and additional screens can be added to confirm outliers depending on the phenotype detected.
*G3 mice mothered by G2 females that do not carry the Cdh23
ahl allele.
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encompasses a large number of disease systems and ensures data
reproducibility and integrity. The design of the pipeline
considered carefully the timing and order of the phenotyping
tests to ensure that we minimized the impact of individual tests
on other phenotype outcomes. For each G3 pedigree the
production of dual cohorts provided an opportunity to explore
in more detail phenotypes detected in the first cohort and to add
complementary phenotype tests. The scale of the screen
precluded a complete pathological examination of tissues from
all G3 mice produced, but this was carried out on selected mice to
assist in the confirmation or determination of a phenotype.
We have analysed 157 pedigrees to date, out of which 134 are
complete and 23 are currently active (Table 2). The average
pedigree size was 102 mice and a total of 13,601 G3 animals have
been generated and phenotyped from the 157 pedigrees.
Phenotype detection and MouseBook. We devised a high-
throughput automated phenotype-detection strategy, alongside a
resource to visualize the phenotyping data. We defined a mutant
line as one where multiple affected G3 mice (Z3) in a pedigree
display very similar phenotypes. All raw data from the pheno-
typing platforms was initially captured into local laboratory
information management systems according to the data
standards defined in the IMPReSS database. Following quality
control procedures, a step-wise strategy was devised to detect
outliers from temporal data in ENU pedigrees. Briefly, we used a
reference range approach that established percentile values for the
entire data set that provides high and low critical values,
approximately equating to ±2 s.d. Parameter values outside of
these critical values for three or more animals in a pedigree led to
a phenodeviancy call. Subsequently, phenodeviant mice were
annotated with the appropriate phenotype (MP term) as specified
by IMPReSS. All raw data and automatically annotated
phenotype data are available via the publically accessible data
portal MouseBook (http://www.mousebook.org/).
To assess the false positive rate (FPR) of the reference range
method, we calculated the FPR of wild-type C57BL/6NTac animal
data from the IMPC project as a test data set. IMPC uses similar
phenotype procedures to the ageing project. We then modelled
the ageing pedigrees by sampling random IMPC baseline animals
to produce a simulated pedigree and employed the reference
range method on each procedure. Wild-type animals should not
be called as outliers therefore any positive calls from the method
are classed as false positive calls. Using simulated pedigrees,
we detected between 0.58 and 1.22% phenodeviance, suggesting a
low average FPR of 0.71% across the procedures examined
(Supplementary Table 1).
Categorical data, such as X-ray abnormalities, were scored as
potential mutants when observed in multiple affected G3 mice
(Z3) in a pedigree. We also, on occasion, considered mice as
phenodeviant when outliers were o2 s.d. from the mean but
where deviations were sustained over multiple time points or,
alternatively, additional phenotyping data confirmed a phenotype
was present. Each putative mutant was confirmed by one or all
of the following; appropriate statistical analyses of primary
phenotyping data, comparison of data from other relevant
phenotypic tests, inheritance testing and mapping data.
Mutant lines. In total, 105 distinct mutant lines were identified in
72 out of 157 pedigrees completed or currently undergoing
analysis (Supplementary Table 2). The mean number of affected
G3 mice for each line was 6.1, with a range from 2 to 17 (Fig. 1a).
Figure 1b demonstrates the distribution of the number of
mutations detected per pedigree. Some pedigrees had multiple
segregating mutations, which may reflect the size of the pedigrees
and the inherent chance of detecting multiple affected mice for
distinct genetic lesions.
Abnormal phenotypes were identified throughout the lifespan
of the pedigrees (Fig. 1c). Visible anomalies such as coat colour
variations, dysmorphologies and extreme behavioural abnormal-
ities were often detected during initial husbandry practices early
in the pipeline before scheduled screens took place. Between 3
and 6 months the first round of tests uncovered a large number of
additional phenotypes. Most importantly, of the 105 mutant lines
identified, 27 were only detected after 6 months (Fig. 1c).
Mapping and mutation detection. Individual mutations were
mapped utilizing the Illumina Medium Density SNP mapping
panel, which is informative at over 900 single-nucleotide poly-
morphisms (SNPs) for the C3H.Pde6bþ and C57BL/6J strains.
The genotypes of affected animals were compared with those of
unaffected individuals from the same pedigree, generally resulting
in a map location of around B20Mb. Following mapping, we
carried out whole-genome sequencing (WGS) of the G1 founder
male, or, on occasion, an affected G3. A local database was
developed to manage the WGS data from G1 mice. All WGS data
was analysed through a standard next-generation sequencing
(NGS) pipeline. The MouseBook portal holds the complete range
of ENU mutations identified in G1 mice (noncoding and coding
mutations) and within noncoding regulatory regions (such as
lincRNAs, miRNAs and promoter regions) annotated from WGS
analysis pipeline. This archive includes all ENU mutations
identified during NGS, including all incidental mutations that
have not been associated with a phenotype. This data set
enabled rapid identification of all mutations segregating within
the sequenced pedigrees and this information, combined with the
map location of the phenotype, allowed us to determine the
causative ENU-induced genetic lesion with high confidence.
Table 2 | Summary of output from the ENU screen including number of pedigrees analysed along with mutant discovery and
mutations cloned.
Total Early Late
Pedigrees 157 — —
Active pedigrees 23 — —
Pedigrees with phenotypes 72 58 26
Number of mutants 105 78 27
Mapped mutations 81 58 23
Cloned mutations 44 32 12 Missense Stop gained Splice mutant
19*/9 10/1 3/2
IAP, intracisternal A-particle.
One late and one early mutation result in an amino acid change but also affect splicing. Early phenotypes were defined as those identified in the first rounds of screening before 6 months of age, with late
phenotypes being those detected after this time.
*Note that one mutation is the result of a spontaneous IAP insertion that appears to have occurred on the C3H background.
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For the 105 lines identified we have currently mapped 81. WGS
of 28 G1 and 8 G3 mice identified the gene lesion underlying
the observed phenotype in 44 mutant lines (Table 2 and
Supplementary Table 2). For individual pedigrees that contained
multiple segregating phenotypes (Fig. 1b) we were able to
identify several causative mutations from a single-G1 sequence.
Some obvious candidate genes are undergoing individual gene
sequencing and some phenotypes were not of sufficient impact to
warrant WGS. For three of the mapped mutations analysed
(all early phenotypes) we failed to uncover a coding lesion, and
these may represent functional changes in noncoding DNA. One
coding lesion was identified as an intracisternal A-particle
insertion that appears to have occurred spontaneously on the
C3H.Pde6bþ background pedigree MPC-59, disrupting
the Mcr1 gene and resulting in a yellow coat colour
(Supplementary Table 2). Out of the 27 ageing phenotypes, 23
have been mapped and for 12 late-onset mutant lines we have
identified and confirmed the underlying mutation (Table 3).
Genetic and phenotypic analysis of mutants. We carried out a
high-level ontological analysis of the distribution of phenotypes
across disease areas investigated by our phenotyping pipeline. The
total number of phenotypes observed across different phenotypic
areas is shown in Fig. 2. Where a single line exhibited more than
one phenotype resulting from the pleiotropic effects of the
underlying mutation we have listed all the phenotypes detected.
In the majority of phenotypic areas we have identified late-onset
phenotypes, but for some categories we have uncovered no
late-onset models. For example, dysmorphology mutants are
overt abnormalities normally associated with developmental
defects, and hence are unlikely to develop late in life.
Table 3 summarizes the genes that have been identified for
late-onset phenotypes. In each case, we have either uncovered a
gene for which there was no prior functional information, or
alternatively, we have assigned novel functionality to a gene with
known functions. For these mutants there is only a single medium
or high-confidence coding mutation in the minimal mapping
region and for laminin alpha 5 (Lama5) and tryptophanyl tRNA
synthetase 2, mitochondrial (Wars2) (pedigrees MPC-205 and
MPC-151, respectively) we have carried out complementation
studies using a knockout (KO) allele to confirm these mutations
as the causative allele (Table 3). In most cases, we also have
identified functional alterations associated with the mutation that
could account for the observed phenotype but, as these studies are
ongoing, in several cases the causal link between mutation and
phenotype are yet to be proven conclusively. Several examples in
diverse biological areas serve to illustrate this powerful discovery
platform for models of age-related disease.
We identified a missense mutation (E884G) in the Lama5 gene
that results in a progressive nephrotic syndrome. G3 mice were
identified at 6 months of age with elevated plasma urea
and creatinine levels, and with reduced plasma albumin
(homozygotes, n¼ 6, versus wild-type, n¼ 33, Urea: 32.9±19.9
versus 5.9±1.1mmol l 1, Po0.05, creatinine: 50.4±37.1
versus 11.45±3.6 mmol l 1, Po0.05, Albumin 16.6±1.6 versus
32.2±1.8 g l 1, Po0.05, Tukey’s multiple comparison test).
Mice reached end-stage renal failure between 7 and 10 months
of age. Lama5 has previously been shown to be critical in organ
development14 and is associated with polycystic kidney disease15,
but this is the first report of its involvement in a chronic renal
phenotype. Recent sequencing data has identified Lama5
mutations in focal segmental glomerular sclerosis patients16.
Thus, this novel mutant provides supporting evidence for a role
for LAMA5 in nephrotic syndromes and will enable the
investigation of the pathogenic processes involved.
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Figure 1 | Summary statistics for mutation discovery in the Harwell
ageing Screen. (a) The distribution of the numbers of affected mice
observed for each mutation within the G3 pedigrees. For lines with low
numbers of affected mice, putative mutations were confirmed by
inheritance testing and/or cloning of the underlying mutation. (b) The
distribution of the number of mutations identified per pedigree from a total
of 105 mutant lines identified from a total of 157 pedigrees. (c) The
distribution of mutation discovery over time. The time point of the initial
identification of an individual phenotype is represented here for a total of
105 mutant lines identified in the screen to date. Where mutants were
outliers in more than one phenotypic test the time point of the first test to
reveal an abnormality is shown.
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Our studies also revealed a mutation in the aggrecan (Acan)
gene in pedigree MPC-227, causing an A1946V substitution in
the C-type-lectin domain, which results in late-onset joint
deterioration and obesity, both novel phenotypic associations
with this locus (Supplementary Fig. 2). By 12 months of age
mutant mice have an altered body composition with a
significantly higher percentage fat mass (Supplementary
Fig. 2a). In contrast to the late-onset obesity, throughout life
homozygous AcanA1946V mice have significantly lower absolute
lean mass (Supplementary Fig. 2b). So, while metabolically obese,
mutant mice are not heavier overall than littermates
(Supplementary Fig. 2c). At 18 months of age mutant mice
exhibit on X-ray bony deposits, particularly in the knee joints
(Supplementary Fig. 2d,e). Existing mouse mutants17,18 have not
Table 3 | Examples of phenotypes and mutations identified as part of the Harwell Ageing Screen.
Pedigree Phenotypic
domain
Phenotype(s) Age of
detection
(months)
Gene CDS base
change
Amino acid
change
Supporting
data
Current MGI
alleles
Current MGI
phenotypes
PubMed
gene hits
MPC-96 Deafness Age-related
hearing loss
Z9 Slc4a10 1940T4C L647P a 1 targeted null Behaviour
Growth/size
Homeostasis
Mortality/
aging
Nervous
System
28
MPC-102 Neuro-
degeneration
Gait
abnormalities
Z12 Eftud1 2948A4G K983R a None Glioma 4
MPC-151 Deafness (a) Progressive
hearing loss
(b) Reduced fat
mass
(a) 3
(b) 7
Wars2 349G4T V117L
(þ splicing
defects)
a, b 2 targeted null Mitochondrial
function
GWAS
adiposity
7
MPC-173 Vision
Deafness
(a) Deafness
(b) Progressive
corneal opacity
(a) Z3
(b) Z9
Ikzf2 1551C4A H517Q a 2 targeted null T-cell
differentiation
Reduced
growth
Increased
mortality
Abnormal
eyelid
development
51
MPC-178 Cardiac Hypertrophic
cardiomyopathy
6 Ecsit 626G4T N209I a 1 targeted null Embryonic
lethal
28
MPC-200 Skin
Pathology
Epidermal and
follicular
hyperkeratosis
Z12 Ces2F 1286A4T Q429L a None None 0
MPC-201 Vision (a) Progressive
reduction in
visual acuity
(b) Retinal
degeneration
(a) Z12
(b) Z12
Idh3a 685G4A E229K a None Retinitis
Pigmentosa
29
MPC-205 Deafness Progressive
hearing loss
Z6 Ptprq 5945þ 2T4C Donor splice a 4 targeted Postnatal
deafness
253
MPC-205 Renal
Function
(a) Elevated
creatinine/urea
(b) Renal failure
(a) 6
(b) 10–12
Lama5 2651A4G E884G a, b One gene trap
Four targeted
Development
Renal Function
Hom null lethal
96
MPC-227 Body
Composition
Musculo-
skeletal
(a) Low-fat
Mass
(b) High-fat
mass
(c) Joint
deterioration
(a) 3
(b) 18
(c) 15
Acan 5837C4T A1946V a Three
targeted null
1 ENU induced
Two
spontaneous
Craniofacial
Growth/size
Achondroplasia
4,246
MPC-236 Neuro-
behaviour
Neurological
(a) Sleep
abnormalities
(b) Motor
function
deterioration
(a) 4
(b) 12
Vamp2 305T4A I102N a Three
targeted null
Synaptic
vesicle function
Growth/Size
Mortality/
Ageing
Hom null lethal
624
MPC-264 Deafness Progressive
hearing loss
Z6 Zfyve26 3943C4T R1315X a 1
Endonuclease
mediated
Spastic
paraplegia
16
ENU, N-ethyl-N-nitrosourea.
The candidate gene, base change and amino acid change are indicated. Supplementary Information details whether (a) if this was the only medium or high-confidence coding mutation in the minimal mapping
region and (b) where genetic complementation with a knockout allele has been carried out. We list the existing alleles documented onMGI along with the current phenotypic associations derived fromMGI. The
number of PubMed hits obtained by the gene name or synonyms is also provided. Slc4a10, ENSMUST00000112480; Eftud1, ENSMUST00000039881; Wars2, ENSMUST00000004343; Ikzf2,
ENSMUST00000027146; Ecsit, ENSMUST00000180180; Ces2F, ENSMUST00000076384; Idh3a, ENSMUST00000167866; Ptprq, ENSMUST00000050702; Lama5, ENSMUST00000015791; Acan,
ENSMUST00000032835; Vamp2, ENSMUST00000021273; and Zfyve26, ENSMUST00000021547. MGI, Mouse Genome Informatics. GWAS, GenomeWide Association Study. CDS, Coding DNA Sequence.
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recapitulated the early-onset osteoarthritis observed in patients
with mutations in this gene19,20. In addition to the quantitative
differences in fat mass, histopathology revealed qualitative
differences in fat tissues. Adipocytes from white adipose tissue
in AcanA1946V mice are enlarged and there is evidence of
inflammatory cell inflammation (Supplementary Fig. 2f,g).
Conversely, the brown adipose tissue shows reduced
accumulation of fat in the mutant mice (Supplementary
Fig. 2h,i). Aggrecan expression has been identified in several
cell types within adipose tissue, including preadipocytes and
pericytes, and can influence adipogenesis21.
Slc4a10 is a novel late-onset hearing loss gene. We have
uncovered several novel genes associated with progressive and/or
late-onset hearing loss, including solute carrier family 4, sodium
bicarbonate transporter, member 10 (Slc4a10), Wars2, protein
tyrosine phosphatase, receptor type, Q (Ptprq) and zinc finger,
FYVE domain containing 26 (Zfyve26). Here we elaborate the
phenotype and characterization of the Slc4a10 late-onset hearing
loss mutant, which exemplifies the novel insights into gene
function and molecular mechanisms associated with late-onset
disease. Auditory phenotyping of pedigree MPC-96 at 3, 6, 9 and
12 months of age found all mice displayed a normal response to a
clickbox stimulus. However, when assessed using auditory-evoked
brainstem response (ABR) testing six mice were found to have
mildly elevated hearing thresholds at 9 months of age thus
indicating an impaired hearing function (Supplementary Fig. 3a).
Subsequent screening of this pedigree at 12 months of age found
these six mice had a further increase in their hearing thresholds
suggesting a progressive phenotype (Supplementary Fig. 3b).
After further breeding no hearing impaired mice were observed in
the backcrossed G4 litters. However in the inter-crossed G5 litters
mice with reduced hearing were identified, indicating a recessive
inheritance.
A genome scan of G3 mice showed linkage to aB63Mb region
on chromosome 2 containing 936 genes. Subsequent mapping
narrowed the critical interval to B12.5Mb (Supplementary
Fig. 4a). Analysis of the WGS data identified only a single
high-confidence non-synonymous coding change within the
mapped interval, consisting of a T-to-C transition at nucleotide
1940 of the Slc4a10 gene (Ensembl transcript ID
ENSMUST00000112480) causing a leucine-to-proline substitu-
tion at residue 647 (Supplementary Fig. 4b) A list of noncoding
mutations in the minimal mapping region identified through
WGS is shown in Supplementary Table 3. The presence of this
lesion was confirmed using Sanger sequencing (Supplementary
Fig. 4b). Only mice showing late-onset hearing impairment were
homozygous for the L647P ENU-induced mutation. The L647
residue is within the transmembrane helix-containing domain of
the protein (Supplementary Fig. 4c) and is conserved across
species (Supplementary Fig. 4d). This mutation was predicted
to be deleterious: SIFT, affect protein function (0.00);
PolyPhen-2, probably damaging (0.986); and Mutation Taster,
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Figure 3 | ABR phenotyping of trombone mice from 2 to 12 months of age. Minimum auditory detection thresholds (decibel SPL (dB SPL)) were
determined using ABR and scored independently by two operators. (a) At 2 months of age, Slc4a10trmb/trmb (homozygous) mice (n¼44) show only a very
mild elevation in ABR thresholds in comparison with Slc4a10þ /trmb (heterozygous) (n¼ 54) and Slc4a10þ /þ (wild-type) (n¼ 18) littermates. (b) At 6
months of age, the very mild elevation of ABR thresholds is still observed in Slc4a10trmb/trmb mice (n¼ 10) compared with Slc4a10þ /trmb (n¼ 21) and
Slc4a10þ /þ (n¼ 13) littermates. (c) By 9 months of age, Slc4a10trmb/trmb mice (n¼ 26) show significantly elevated ABR thresholds (B20dB shift) across
all frequencies tested compared with Slc4a10þ /trmb (n¼ 25) and Slc4a10þ /þ (n¼6) littermates. (d) At 12 months of age, Slc4a10trmb/trmb mice (n¼ 17)
continue to have elevated thresholds compared with the normal hearing Slc4a10þ /trmb (n¼ 13) and Slc4a10þ /þ (n¼ 7) control mice. In addition, the
average hearing thresholds of Slc4a10trmb/trmb mice increase between 9 and 12 months of age. The Slc4a10þ /trmb and Slc4a10þ /þ control mice do not
show any auditory decline during the first 12 months of life, nor do they show any significant differences between their auditory thresholds at any frequency
or age tested. Black circle/line, Slc4a10þ /þ ; grey square/line, Slc4a10þ /trmb; red triangle/line, Slc4a10trmb/trmb. Data shown are mean ±s.e.m. and
significance determined using a one-way ANOVA with Tukey’s multiple comparisons test comparing Slc4a10trmb/trmb threshold data with the corresponding
Slc4a10þ /þ control data: *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001.
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disease causing (0.999) (refs 22–24). This mouse line was named
trombone (trmb).
To further investigate the auditory phenotype in the trombone
model, additional mice were bred and assessed by clickbox and
ABR at 2, 6, 9 and 12 months of age. All genotypes (Slc4a10þ /þ ,
Slc4a10þ /trmb, and Slc4a10trmb/trmb) displayed a normal Preyer
reflex in response to a clickbox stimulus at all ages tested. In
addition, Slc4a10þ /þ and Slc4a10þ /trmb mice have ABR
thresholds within the normal range at all ages tested. However,
while Slc4a10trmb/trmb mice have similar ABR thresholds to their
Slc4a10þ /þ and Slc4a10þ /trmb controls at 2 and 6 months of
age, by 9 months they have mildly elevated ABR thresholds at all
tested frequencies (Fig. 3). At 12 months of age the auditory
thresholds of Slc4a10trmb/trmb mice are further elevated, display-
ing an increase ofZ10 dB sound pressure level (SPL) at 8, 16 and
32 kHz, indicating a progressive late-onset auditory impairment
(Fig. 3). In addition, no overt vestibular dysfunction (for example,
circling, head bob, abnormal swim), craniofacial dysmorphology
or weight phenotype were observed.
To assess the ultrastructure of the cochlear sensory epithelium
scanning electron microscopy was undertaken (Fig. 4).
Slc4a10þ /þ and Slc4a10þ /trmb mice display the expected
complement of inner hair cells and outer hair cells (OHCs) up
to 12 months of age, the latest age tested. At 2 and 6 months of
age Slc4a10trmb/trmb mice also display the expected number of
inner hair cells and OHCs, with no differences in shape or
organization of their stereocilia bundles (Fig. 4a). However, by 9
months of age OHC bundle loss is evident in Slc4a10trmb/trmb
mutant mice, and this loss progresses such that by 12 months of
ageo50% of OHC bundles remain (Fig. 4a). To quantify the loss,
counts were made in the apical, mid and basal turns of the
cochlea (Fig. 4b). This shows that in Slc4a10trmb/trmb mice OHC
bundle loss is occurring along the length of the cochlear spiral.
There is no evidence of OHC bundle loss in Slc4a10þ /þ and
Slc4a10þ /trmb mice up to 12 months of age.
To assess the expression of Slc4a10 within the cochlea,
mid-modiolar histological sections were prepared and immunos-
tained using an anti-Slc4a10 antibody. For Slc4a10þ /þ and
Slc4a10þ /trmb cochlear sections, immunohistochemical staining
was observed in the spiral ligament (SL) fibrocytes throughout all
cochlear turns at 2, 6, 9 and 12 months of age (Fig. 5a). The
strongest staining was detected in the type II fibrocytes beneath
the spiral prominence and the type V fibrocytes in the suprastrial
region. There was no staining of additional cochlear structures,
for example, organ of Corti (OoC), Reissner’s membrane (RM),
or spiral ganglion neurons (SGN) (Fig. 5a). For Slc4a10trmb/trmb
cochlear sections no staining of the SL was detected at any of the
time points tested, implying a loss-of-function mutation (Fig. 5a).
In addition, assessment of the cochlear sections identified a
similar number of SGNs present across all genotypes at each time
point investigated (2, 6, 9 and 12 months of age) (Fig. 5b).
To assess the consequence of the trombone mutation on the
structure of the cochlear lateral wall morphometric analyses
were performed. Utilizing hematoxylin and eosin stained
mid-modiolar cochlear sections the cross-sectional surface area
of the SL, and the closely apposed stria vascularis (SV), were
measured in the mid-basal cochlear turn. This identified that the
cross-sectional surface area of the SL was consistent across all
genotypes, at all ages (Fig. 5c). Assessment of the SV identified
that the cross-sectional surface area was similar between
Slc4a10þ /þ and Slc4a10þ /trmb mice at each time point.
However, the cross-sectional surface area of the SV was reduced
by 420% in Slc4a10trmb/trmb mice (Fig. 5d). Interestingly,
SL and SV nuclei counts demonstrate there is not a
statistically significant difference in the total number of cells
within either of these structures across genotype (Slc4a10þ /þ ,
Slc4a10þ /trmb and Slc4a10trmb/trmb) or age (2, 6, 9 and 12
months) (Fig. 5e,f).
The SV is critical for generating the extracellular fluid
(endolymph) found in the scala media, which bathes the apical
surface of the auditory sensory cells. By pumping Kþ into the
scala media the SV generates a high Kþ concentration and large
electrical potential, known as the endocochlear potential (EP), in
this extracellular space compared with that of the perilymph-
containing scala tympani. The EP is essential for the process of
auditory transduction, establishing an electrochemical gradient
that drives cations from the endolymph into the sensory cells via
mechanically gated channels to cause depolarization of, and
subsequent neurotransmitter release from, the sensory cells in a
process known as mechanoelectrical transduction. To assess if SV
function is compromised, the EP was measured in trombone mice
at 2, 9 and 12 months of age. At 2 months of age the averaged EP
values for Slc4a10þ /þ and Slc4a10þ /trmb mice were similar at
76mV (range 62–89mV) and 77mV (range 53–89mV),
respectively. However, the averaged EP value for age-matched
Slc4a10trmb/trmb mice was significantly lower at 40mV (range
29–55mV) (Fig. 5g). At 9 months of age the averaged EP values
for Slc4a10þ /þ and Slc4a10þ /trmb mice were 73mV (range
57–82mV) and 59mV (range 40–69mV), respectively. Again, the
averaged EP value for age-matched Slc4a10trmb/trmb mice was
significantly lower at 32mV (range 27–41mV) (Fig. 5g). At 12
months of age, the averaged EP values for Slc4a10þ /þ and
Slc4a10þ /trmb mice were 65mV (range 42–82mV) and 55mV
(range 44–81mV), respectively; whereas the averaged EP value
for age-matched Slc4a10trmb/trmb mice was significantly lower at
28mV (range 15–46mV) (Fig. 5g). The observed age-related
decline in EP is only significant for the Slc4a10þ /trmb mice
(Po0.0001).
Recent studies of an Slc4a10 targeted KO mouse mutant
(Slc4a10 / ) have identified a role for Slc4a10 in maintaining
intracellular chloride and bicarbonate concentration in retinal
neurons, demonstrating that loss of Slc4a10 in the retina leads to
impaired visual function in the Slc4a10 / KO mouse25. To
ascertain if the Slc4a10trmb/trmb mice also display a retinal
phenotype electroretinography (ERG) was undertaken. To enable
this, the trombone allele was rederived on, and backcrossed to,
C57BL/6J, a strain suitable for ERG studies. The ERG analysis
showed that trombone mice display a very similar, albeit milder,
retinal phenotype to the Slc4a10 / KO mice (Supplementary
Fig. 5a). Overall, compared with wild-type littermate mice,
Slc4a10trmb/trmb mice showed: grossly similar dark-adapted
irradiance-response curves for a- and b-waves (Supplementary
Fig. 5b,c) significant differences in phase/timing of flicker
frequency responses (delayed in mutant) especially in 7–15Hz
responses (Supplementary Fig. 5d); and, smaller and slower light-
adapted responses showing significant differences in amplitude
and implicit time at higher flash intensities (Supplementary
Fig. 5e–i). The similar phenotype supports our hypothesis that
the trombone allele causes loss-of-function. In summary, the
trombone mutant (Slc4a10L647P) underlines the utility of
characterising mutations with late-onset phenotypes, uncovering
novel genes and insights into the underlying molecular
mechanisms. Age-related hearing loss in trombone mice is
preceded by changes to the structure of the SV and by defects
in endocochlear potential.
Discussion
We have established a large-scale ENU G3 recessive screen for
age-related disease phenotypes. The aim has been to provide a
wider understanding of the genetic pathways that contribute to
disease in an ageing context. Overall, we have demonstrated that
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ENU phenotype-driven screens have the capacity to uncover
a significant number of phenotypes that display late-onset
disease and which are caused by mutations in novel genes,
hitherto not associated with known functions in age-related
disease. In total we have examined over 150 G3 pedigrees,
identifying 105 distinct mutant lines, including 27 lines with
late-onset phenotypes.
A significant number of pedigrees revealed multiple pheno-
types in our screening pipeline. This is not surprising given the
large size of the pedigrees and the relatively comprehensive
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Figure 4 | Ultrastructural analyses of the cochlear sensory epithelium reveals progressive loss of hair cell bundles in trombone mutant mice.
(a) Scanning Electron Micrographs of the mid-basal coil of the cochlear sensory epithelium from Slc4a10þ /þ , Slc4a10þ /trmb, Slc4a10trmb/trmb mice at 2, 6,
9 and 12 months of age. At 2 and 6 months of age, the number and appearance of the inner and outer hair cell stereocilia bundles are is as expected and
similar across all three genotypes. At 9 months, there is some loss of outer hair cell bundles in the Slc4a10trmb/trmb mutant mice, which is not observed in
the Slc4a10þ /þ and Slc4a10þ /trmb control mice. By 12 months of age, there is a substantial loss of outer hair cell bundles in the Slc4a10trmb/trmb mutant
mice, which is not observed in the Slc4a10þ /þ and Slc4a10þ /trmb control mice. Magnification  2,500. Scale bars, 10mm (b) Outer hair cell bundle counts
in the apical, mid and basal turns of the cochlear spiral in trombonemice. At 2 months of age Slc4a10þ /þ (apex n¼ 5, mid n¼ 7, base n¼ 5), Slc4a10þ /trmb
(apex n¼ 3, mid n¼ 6, base n¼ 3), Slc4a10trmb/trmb (apex n¼ 5, mid n¼4, base n¼ 3) mice all have similar numbers of OHC bundles. At 6 months of age
Slc4a10þ /þ (apex n¼ 3, mid n¼ 3, base n¼ 3), Slc4a10þ /trmb (apex n¼4, mid n¼ 3, base n¼4), Slc4a10trmb/trmb (apex n¼ 3, mid n¼ 3, base n¼ 3) mice
all still have similar numbers of OHC bundles. However, by 9 months of age Slc4a10trmb/trmb (apex n¼ 3, mid n¼ 3, base n¼ 3) mice have a reduced number of
OHC bundles in all cochlear regions compared with Slc4a10þ /þ (apex n¼ 3, mid n¼ 3, base n¼ 3), Slc4a10þ /trmb (apex n¼ 2, mid n¼ 3, base n¼ 3) mice.
At 12 months of age Slc4a10trmb/trmb (apex n¼ 5, mid n¼ 3, base n¼ 6) mice show a further loss of OHC bundles in all cochlear regions compared with
Slc4a10þ /þ (apex n¼ 2, mid n¼ 3, base n¼ 2), Slc4a10þ /trmb (apex n¼4, mid n¼ 6, base n¼ 3) mice. Although Slc4a10trmb/trmb mice show a
progressive loss of OHC bundles throughout the cochlear spiral, no significant OHC bundle loss is observed in the Slc4a10þ /þ or Slc4a10þ /trmb mice up to
12 months of age. Slc4a10þ /þ (black bars), Slc4a10þ /trmb (grey bars), Slc4a10trmb/trmb (red bars). Data shown are mean ±s.e.m. and significance
determined using a two-way ANOVA with Tukey’s multiple comparisons test: **Po0.01, ***Po0.001, ****Po0.0001.
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phenotype screens that we have undertaken. However, most
importantly, we find that around one quarter of all mutant
phenotypes are detectable from 7 months onwards, indicating
that a significant number of mutations leading to alterations in
gene function are only manifest in an ageing context. This high
hit rate indicates that the ongoing analysis of further pedigrees
will be a productive route for the recovery of considerable
numbers of additional age-related disease loci.
Employing a high-level ontological analysis, it is clear that we
have identified late-onset phenotypes, which span a wide disease
spectrum. We would expect that the random nature of ENU
mutagenesis provides an unbiased route to the identification of
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late-onset disease loci. Our data support the conclusion that this
approach represents a powerful approach for revealing late-onset
phenotypes in any disease domain, as much as it has already been
shown to be a productive approach for the identification of
early-onset phenotypes3,4,6.
We have employed WGS to identify the mutations underlying
individual phenotypes. This approach revealed the sequence
alteration in 44 out of 47 mutant phenotypes investigated. The 44
mutations identified comprised missense, splice site, nonsense
mutations and an intracisternal A-particle insertion, in each case
likely to compromise gene function. A wide range of ENU
mutagenesis programmes have reported a very high frequency of
coding changes, particularly missense, that underlie mutant
phenotypes and our results are in agreement with these findings.
For three mutant phenotypes investigated there are no coding or
splice-site mutations that could account for the observed
phenotype. It is unclear whether or not the functional change is
located in noncoding sequences, but the availability of whole-
genome sequence allows us to document all the sequence variants
in the mapped region and potentially to test individual variants.
Out of 27 late-onset phenotypes we have so far identified the
underlying lesion in 12, and additional mutations remain to be
confirmed. We report in Table 3 the novel gene functionality that
has been revealed. These results indicate the power of phenotype-
driven ENU mutagenesis screens, which make no a priori
assumptions about gene function or the pathways involved in
disease, to uncover novelty, in this case the underlying basis of
age-related disease. In several cases, the identification of novel
genes and pathways are likely to open up new lines of enquiry
into the physiological and pathological bases of late-onset
phenotypes.
As an example of the novel gene function associated with
ageing phenotypes, we report the characterization of the
trombone late-onset hearing loss mutation. The trombone mice
display a late-onset progressive hearing loss, which is due to a
loss-of-function mutation in the sodium-coupled bicarbonate
transporter (NCBT), Slc4a10. Before this investigation, Slc4a10
has not been reported to be associated with auditory dysfunction
in the mouse or in human studies. However, a study has shown
that Slc4a10 KO mice have smaller brain ventricles and an
increased threshold to experimentally induced seizures compared
with wild-type animals. They also report that Slc4a10 is important
for regulating neuronal intracellular pH and excitability, and
suggest that because Slc4a10 is involved in solute transport within
the epithelial cells of the choroid plexus it is likely to contribute to
secretion of cerebrospinal fluid26. Interestingly, Slc4a7, another
NCBT closely related to Slc4a10, has been linked to auditory
dysfunction and retinal impairment. Slc4a7 also acts to maintain
intracellular pH playing a vital role in the efficient disposal of acid
(Hþ ) generated by neuronal and sensory receptor activity, which
is an essential requisite of sensory transduction. Mice lacking
Slc4a7 develop auditory impairment and blindness due to
degeneration of sensory receptors in the inner ear and eye,
respectively27. Auditory impairment in these mice is present from
one month of age, and is concomitant with loss of hair cells and
morphological changes in the SV and SL. In addition to the very
similar phenotype, the expression pattern of Slc4a7 is the same as
Slc4a10, with expression in the type II and type V cochlear
fibrocytes. It was hypothesized that impaired ion transport by the
SL fibrocytes in Slc4a7 KO mice may lead to hair cell
degeneration and consequently auditory impairment.
Currently very little is known regarding the pathological
changes occurring within the human auditory system that result
in age-related hearing loss, also known as presbycusis. However,
seminal work by Schuknecht has led to several pathological
subtypes of presbycusis to be proposed; these include: ‘sensory’,
involving hair cell loss; ‘strial’, involving degeneration of the SV
and reduction in EP; and ‘neural’, involving loss of SGNs28–30.
The hearing impairment observed in trombone mice is
concomitant with a progressive loss of OHCs, but the
underlying mechanism likely involves a chronically reduced EP
that precedes OHC loss and hearing impairment. As such, our
findings suggest that trombone is likely a model of strial
presbycusis, and that Slc4a10 is a candidate gene for human
age-related hearing loss. Furthermore, trombone will serve as a
model to learn more about the functional requirement of
bicarbonate transporters in the lateral wall and as a model to
test the efficacy of gene-delivery techniques to target the cochlear
lateral wall and ameliorate hearing loss.
Ageing screens as described here have the potential to provide
models that will underpin improved preclinical studies of
therapeutic interventions, particularly as the disease occurs in
the context of an ageing physiology. Many mouse models
currently used to develop therapies for age-related and chronic
diseases have early-onset phenotypes that are often acute. As a
consequence, potential therapies are assessed against the
background of a rapid and aggressive disease. Moreover,
pharmacodynamics may change with ageing; for example
immunosenescence will influence the effect of immunization in
the aged31, while mitochondrial dysfunction can result in adverse
drug reactions32. Thus the models of age-related disease
we are identifying will not only aid our understanding of
disease pathogenesis but also provide more refined preclinical
models with a greater window of opportunity for therapeutic
intervention.
In conclusion, we have established a large-scale phenotype-
driven screen for genes associated with age-related disease and
successfully identified mutants resulting in such pathologies.
Figure 5 | Cochlear expression of Slc4a10 morphology of the lateral wall and endocochlear potential in trombone mice. (a) Immunohistochemical DAB
staining of cochlear sections identifies Slc4a10 expression in the SL fibrocytes of Slc4a10þ /þ and Slc4a10þ /trmb mice. No DAB staining of Slc4a10trmb/trmb
sections is observed at any of the time points tested. Scale bar, 600 mm. Number of cochleae imaged (one per mouse) for each genotype at 2-, 6-, 9- and 12
months of age were: Slc4a10þ /þ n¼ 5, 5, 6, 6; Slc4a10þ /trmb n¼ 7, 4, 5, 6; and Slc4a10trmb/trmb n¼4, 3, 5, 6, respectively. (b) SGN counts in Slc4a10þ /þ ,
Slc4a10þ /trmb and Slc4a10trmb/trmb mice shows there are no differences across genotype, or with age. Counts averaged from individual mice (N¼ 3) for
each genotype at each age. (c) Analysis of the cross-sectional surface area of the SL shows there are no differences across genotypes, or with age.
(d) Analysis of the SV show there is a significant reduction in the cross-sectional surface area in Slc4a10trmb/trmb mice compared with Slc4a10þ /þ and
Slc4a10þ /trmb mice, and this is consistent across the ages tested. The SL and SV surface areas are averaged from individual mice for each genotype at 2-,
6-, 9- and 12 months of age: Slc4a10þ /þ n¼ 5, 3, 5, 5; Slc4a10þ /trmb n¼ 7, 5, 8, 5; and Slc4a10trmb/trmb n¼ 5, 6, 7, 6, respectively. (e,f) Comparison of SL
and SVnuclei counts shows there are no differences across genotype, or with age. The nuclei counts are averaged from individual mice for each genotype at
2-, 6-, 9- and 12 months of age: Slc4a10þ /þ n¼ 5, 3, 3, 3; Slc4a10þ /trmb n¼ 5, 4, 4, 3; and Slc4a10trmb/trmb n¼6, 5, 4, 3, respectively. (g) The
endocochlear potential is chronically reduced in Slc4a10trmb/trmb mice compared with controls. Measurements averaged for each genotype at 2-, 9- and 12
months of age: Slc4a10þ /þ n¼6, 6, 8; Slc4a10þ /trmb n¼ 10, 12, 11; and Slc4a10trmb/trmb n¼ 8, 6, 9, respectively. Slc4a10þ /þ (black circles/bars),
Slc4a10þ /trmb (grey circles/bars), Slc4a10trmb/trmb (red circles/bars). Data correspond to mean±s.e.m., and statistical significance determined using
two-way ANOVA with Tukey’s multiple comparisons test. *Po0.05; **Po0.01; ***Po0.001, ****Po0.0001. ANOVA, analysis of variance.
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These novel mutants will not only aid our understanding of
pathogenic processes occurring during ageing but act as robust
preclinical models of disease.
Methods
Mice. All animals were housed and maintained in the Mary Lyon Centre at MRC
Harwell, under specific pathogen-free conditions in individually ventilated cages,
with environmental conditions as outlined in the Home Office Code of Practice.
Home Office ethical approval was granted under project licence 30/3070 and mice
were killed by Home Office Schedule 1 methods. ERG experiments were performed
at the University of Oxford in compliance with the ARVO statement for the Use of
Animals in Ophthalmic and Vision Research and with relevant institutional and
UK Home Office approval. All screened mice used in this study are G3 animals
with a mixed C3H.Pde6bþ and C57BL/6J genetic background. Further
investigation of the trombone auditory phenotype was undertaken on G4 to G7
mice backcrossed to C3H.Pde6bþ . To enable ERG phenotyping of trombone mice,
the line was rederived by IVF using sperm from the G1 male and backcrossed to
C57BL/6J for two generations before inter-crossing.
Generation of mutagenized pedigrees. The ENU mutagenesis protocol has been
described previously4. The Harwell Ageing Screen is a large-scale ENU mutagenesis
screen to generate mouse models of age-related disease. G3 recessive pedigrees, of
B100 mice, are bred and enter a phenotyping pipeline comprising recurrent
assessment (to 18 months of age) across a wide range of disease areas. Briefly,
C57BL/6J male mice (G0) were treated with ENU doses of 1 120mg kg 1, and
then 2 100mg kg 1 with a week between each dose. The mice were then bred
with wild-type ‘sighted C3H’ (C3H.Pde6bþ ) females11. The resulting G1 males
were bred with wild-type C3H.Pde6bþ females to produce G2 females, which were
genotyped for the hypomorphic Cdh23 allele, ahl112,33. G2 females that were
wild-type for Cdh23 were backcrossed to their G1 fathers to generate G3 offspring.
Some phenotypes, such as glucose tolerance, are strongly modified by sex and
circadian screening necessitated individually housing mice for up to 3 weeks,
thereby limiting the screen to female mice because of the potential problems trying
to rehome males together after being separated or housing males individually for
extended periods Therefore some screens utilised a single sex for the initial
screening but upon identification the other sex was screened as well. The G3 mating
scheme results on average in one in eight G3 mice homozygous for any particular
ENU-induced mutation. Binomial probability calculations indicate that a cohort of
50 single sex mice will yield four homozygotes with a probability ofB85% and five
with a probability ofB75%. Thus we aim for a pedigree size of around 100 to enter
the ageing screen.
Phenotyping platforms. An overview of the phenotyping timetable is presented in
Table 1 and is also summarized in Supplementary Fig. 1b. Additional time points
may be added for specific phenotypes of interest. Furthermore, additional phe-
notypic investigations of individual pedigrees may be undertaken that are unsui-
table for high-throughput application within the core pipeline. These include gait
analysis (Cleversys or Locotronic), metabolic caging, Comprehensive Lab Animal
Monitoring System analysis, optocoherence tomography, as well as behavioural
tests (elevated plus maze, Morris water maze, startle/pre-pulse inhibition). For
some tests a single sex was analysed initially, primarily for logistical reasons,
but if an abnormal phenotype was suspected then the remaining mice were
screened as well.
All primary phenotyping of ENU mutagenized pedigrees is performed blinded
as genotypes are not determined until after a phenotype is identified and the
majority of phenotyping data is analysed post hoc. For downstream analysis
experimenters are blinded to the genotype and mice are housed in cages containing
wild-type, heterozygous and homozygous mutants bred from heterozygous inter-
cross matings, and randomly assigned at weaning before genotyping of individuals.
Linkage analysis and DNA sequencing. DNA from affected mice and littermates
was prepared from ear biopsies and used for linkage mapping utilizing the Illumina
GoldenGate Mouse Medium Density Linkage Panel (Gen-Probe Life Sciences Ltd,
UK). DNA from G1 or affected G3 mice was prepared for either WGS using the
Nucleon BACC2 Genomic DNA Extraction System (GE Healthcare Life Sciences),
a library generated, and a single lane of paired-end sequencing (100 nt) undertaken
employing the Illumina HiSeq platform (Oxford Genomics Centre, Wellcome
Trust Centre for Human Genetics). The paired-end Illumina reads, 100 nt in length
for each G1 was aligned to the reference genome (NCBIM38/mm10) using
Burrows-Wheeler Aligner34. Single-nucleotide variants (SNVs) in each alignment
were detected using the unified GenotypeCaller in the Genome Analysis Toolkit
(GATK)38 with mouse dbSNP version 137 as the background SNP set and default
parameters. SNV sites that obtained a variant quality score o100 (this is a Phred
scaled quality score,  10 log (1 p), where p is the probability of the SNV being
called incorrectly), or had a read depth o3 were removed from any further
analysis. The remaining SNVs, termed high-confidence mutations, were then
compared with the precompiled SNPs found in 17 inbred strains from the Mouse
Genome Project35 and an in-house library of SNVs. The overlapping sites were
removed resulting in a final list of unique ENU SNVs for each G1. These SNVs
were then functionally annotated (for example, missense, intronic and so on) using
NGS-SNP36. All high-confidence mutations are available on MouseBook. For
individual mutant lines SNVs were confirmed by Sanger sequencing of affected
mice.
Data import. Phenotype data was initially captured in different formats including
an in-house LIM system (Anonymus), Excel spreadsheets, structured files (for
example, CSVs) or plain text. For automatic phenotype detection, customised code
was generated for each data type, which imported the data into a common data
format. This data was transferred to a single import engine that validated and then
added the data to the Ageing database as appropriate. Raw data validation was
carried out using the standard operating procedure in IMPRESS and Anonymus.
The former was used to validate phenotype parameter features such as unit type
and the minimum, maximum value whilst the latter was used to validate mouse
features, for example, mouse id, sex, date of birth.
Outlier detection and visualization. To automatically detect potential
phenodeviants we developed approaches to identify animals with abnormal data
values from a genetically mixed data set. Where there is no baseline phenotype data
to identify potential outliers inferential statistical tests are not applicable. We
therefore first constructed a reference range from the whole Ageing pipeline data
set, as commonly used for clinical chemistry data37. For each phenotype parameter
we employed all data values and constructed a reference range by establishing the
percentile positions for the entire data set, providing high and low critical values.
Parameter values above the high critical value, or below the low critical value, are
marked as outliers.
Phenodeviancy calls were made if three or more animals produce a value either
higher or lower (in the same direction) than the calculated reference range.
The range used, 95.8%, approximately equates to ±2 s.d. The exception is ABR
(auditory brainstem response), where two or more animals were used to make a
phenodeviancy call. This approach generated a series of phenodeviancy calls for
each measured time point. When phenodeviancy occured at 450% of the
subsequent time points from the time of onset (that is, it is not a random temporal
outlier) we considered this a positive phenotype call within the pedigree.
Phenodeviancy calls were annotated with the appropriate Mammalian Phenotype
term defined in IMPReSS. Procedure values and phenodeviancy calls are exported
to MouseBook where bespoke graphs and advanced searches for every pedigree,
procedure and parameter combination are displayed.
Determination of false discovery rate. To assess the false discovery rate,
a reference range was created using purely IMPC C57BL/6NTac wild-type data, at a
single time point, using comparable phenotype procedures that are used in the
ageing screen. This produced a set of reference ranges for the 10 matching
procedures and 90 comparable parameters. We then created synthetic pedigrees by
selecting mice at random from IMPC wild-type animals. The pedigree size was
determined by randomly selecting an ageing pedigree, and then employing the
number of animals in the selected pedigree as the size of the IMPC synthetic
pedigree. These pedigree sizes have a mean size of 92 animals and a standard
deviation of 46 (from 157 total pedigrees within the ageing data set). Outliers were
then identified for each random sample, using the previously calculated reference
ranges for each parameter. The number of simulated pedigrees with Z3 outliers
(either high or low) was then recorded. This simulation was then repeated
100,000 to provide an estimation of the FPR for each parameter (number of
outlier calls/total number of samples), and the total number of calls for each
phenotype procedure.
Auditory-evoked brainstem response. Mice were anaesthetized with ketamine
(10%v/v) and xylasine (5% v/v) administered at the rate of 0.1ml/10 g body mass.
Animals were placed on a heated mat inside a sound attenuated chamber.
Electrodes (Grass Telefactor F-E2-12) were placed subdermally over the vertex
(active), right mastoid (reference), and left mastoid (ground). ABR responses
were collected, amplified and averaged using TDT System III (Tucker Davies
Technology, Alachua, FL, USA) in conjunction with SigCal and SigGen (Biosig)
software. Click stimuli consisted of a 0.1ms broadband click of alternating polarity.
Tone-burst stimuli totalled 7-ms duration, including 1ms rise/fall time; frequencies
used were 8, 16 and 32 kHz. Recordings were performed beginning at 95 dB SPL
and decreased in 5 dB increments. ABR thresholds were defined as the lowest dB
SPL level at which an ABR trace pattern could be clearly distinguished. Animals
were recovered using anaesthetic reversal agent Antipamezole (Antisedan, 0.1ml
1% v/v). For the analysis of the trombone model the number of mice tested for each
genotype at 2-, 6-, 9- and 12 months of age were: Slc4a10þ /þ n¼ 18, 13, 6, 7;
Slc4a10þ /trmb n¼ 54, 21, 25, 13; and Slc4a10trmb/trmb n¼ 44, 10, 26, 17,
respectively.
Slc4a10 genotyping. DNA was extracted from ear biopsies and used as template
for PCR in the presence of the double-stranded DNA-binding dye LCGreen, and a
30-blocked oligonucleotide probe that binds directly over the Slc4a10 lesion
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matching the mutant trombone sequence. An asymmetric exhaustive PCR was
performed using five times the amount of reverse primer (and probe) compared
with forward primer. Five microlitre HotShot master mix; 1 ml LCGreen; 0.1 ml
Slc4a10trmb forward—50-CTC GTC TGC TAC ATC ACC C-30 (20 ngml 1); 0.5 ml
Slc4a10trmb reverse—50-CGA GTA TTG TGT CAG CAG TTC-30 (20 ng ml 1);
0.5 ml Slc4a10trmb forward probe—50-GAA GTT GTT TGA GCC CAG TGA AAC
CTA-30-3NHC3 (20 ng ml 1); 2 ml DNA (1/10 dilution); and 0.9 ml ddH20. Cycling
conditions used were: 95 C 2min, then 55 cycles of 95 C 30 s–60 C 30 s–72 C
30 s, followed by probe hybridisation 95 C 30 s–25 C 30 s–15 C 30 s. Hybridised
products were then heated on a LightScanner (Idaho Technology) and the
fluorescence emitted by bound LCGreen was monitored using a high-resolution
melting curve analysis and analysed using manufacturer’s software. As the
probe:PCR amplicon duplex melts the LCGreen dye is released and fluorescence
decreases. The probe matches the mutant sequence and as such melts at a slightly
higher temperature than the wild-type sequence, which harbours a mis-match.
Using this method wild-type, heterozygous and homozygous mutant genotypes can
be identified.
Scanning electron microscopy (SEM). Animals were killed and excised inner
ears were fixed overnight in 2.5% gluteraldehyde in 0.1M phosphate buffer
(Sigma-Aldrich). Fixed ears were decalcified for 48 h in 4.3% EDTA in 0.1M
phosphate buffer (Sigma-Aldrich). Fine dissection was performed to reveal the
organ of Corti, before osmium tetroxide (Agar Scientific)—thiocarbohydrazide
(Fluka) (OTOTO) processing (adapted from ref. 38) was carried out. The inner
ears were then dehydrated through increasing strength ethanol solutions (Fisher
Scientific) and critical point dried using an Emitech K850 (EM Technologies LTD).
The specimens were then mounted on stubs using silver paint (Agar Scientific) and
sputter coated with platinum using a Quorum Q150T sputter coater (Quorum
Technologies). Prepared cochleae were visualised with a JEOL LSM-6010 (Jeol Ltd.)
scanning electron microscope. Hair cell counts were performed by counting the
number of OHCs adjacent to 10 pillar cells, for the analysis the cochlea was divided
into three separate regions (turns), apical (o90 from apex), mid (180–360 from
apex) and mid-basal (360–540 from apex). Ears from at least three mice were
analysed for each genotype at each turn and time point.
Cochlear histology. Mice were killed, heads removed, skinned and bisected along
the midline before fixation in 10% neutral buffered formalin (Surgipath). Fixed
specimens were decalcified, dehydrated and embedded in paraffin wax, 5 mm
sagittal sections were obtained and H&E stained using standard protocols.
Electroretinography. ERG testing was used to examine retinal function in
adult (11–12 week old) mice. N¼ 5 homozygous trombone mutant mice
(Slc4a10trmb/trmb) were tested, with the same number of age and sex matched
homozygous wild-type littermates used as controls. Mice were housed under
standard 12:12 light–dark cycle with food and water available ad libitum.
ERG preparation and testing were performed in a similar manner to that
described previously39. Before testing, mice were dark-adapted overnight (416 h)
and all experimental preparation was performed under dim red illumination.
Animals were anaesthetised via intraperitoneal injection of 80mg kg 1 ketamine
(Vetalar, Pfizer Animal Health, Sandwich, UK) and 10mg kg 1 xylazine
(Rompun, Bayer HealthCare, Newbury, UK) in sterile water for injection. Pupils
were fully dilated with tropicamide and phenylephrine eye drops (Minims
tropicamide 1% w/v and Minims phenylephrine hydrochloride 2.5% w/v, both
Bausch & Lomb, Kingston-Upon-Thames, UK). Animals were placed on a heated
platform, maintained at 38 C using a circulating pump–water bath. A DTL-type
silver-coated nylon thread active electrode (DTL Plus Electrode; Diagnosys LLC,
Cambridge, UK) was modified to include a custom-made contact lens of clear
Aclar film (Honeywell International, Inc., supplied by Agar Scientific, Stansted,
UK). This was positioned concentrically on the cornea using 1% hypromellose eye
drops (Isopto alkaline, Alcon Laboratories, Camberley, UK) to provide good
electrical contact and to maintain corneal hydration. Active electrodes were placed
on both eyes and recorded the ERG of each eye independently. Platinum needle
electrodes in the forehead and at the base of the tail served as common reference
and ground electrodes, respectively. All recordings were made in a custom-made
light-tight Faraday cage. ERG signals were differentially amplified and digitized at a
rate of 5 kHz using an Espion E2 console (Diagnosys LLC, Cambridge, UK)
that also generated and controlled the light stimuli which were delivered in a
Ganzfeld dome.
In dark-adapted testing, an intensity response curve was first generated for
single-flash responses elicited by brief (4ms) flashes of white light (6,500 K light-
emitting diode source) on a dark background. Recording began at the dimmest
stimulus intensity and was then increased across a 47 log unit range ( 6 to 1.4
log cd.s m 2) in up to log unit steps with the following response averaging and
inter-stimulus interval (ISI) times used:  6 to  5 log cd.sm 2; 16 responses
averaged with an ISI of 3 s;  4 to  3 log cd.s m 2; nine responses, ISI¼ 4 s;
 2 log cd.sm 2; nine responses, ISI¼ 8 s;  1 log cd.s m 2; four responses,
ISI¼ 16 s; 0 log cd.s m 2; four responses, ISI¼ 32 s; 1 log cd.sm 2; four
responses, ISI¼ 64 s; 1.4 log cd.s m 2, single response.
After recording the dark-adapted intensity response curve, an increasing flicker
series was recorded at a fixed stimulus flash intensity ( 2 log cd.s m 2). Flicker
ERG responses were recorded at the following rates (Hz): 0.5, 1, 2, 3, 5, 7, 10, 12,
15, 18, 20 and 30. Waveforms were recorded in stimulus synchronised response
epochs (sweeps) of 500ms duration and either 20 (0.5–3Hz) or 30 (5–30Hz)
sweeps were recorded and an averaged response was generated after excluding the
first sweep per step in all cases.
After dark-adapted recordings were completed, animals were exposed to a
full-field 30 cd.s m 2 white background (6,500 K LED source, as stimulus) for at
least 10min. Light-adapted ERGs were then recorded in response to a range of
white flash stimuli ( 0.5 to 1.4 log cd.sm 2 inBhalf log unit steps, 20 responses
averaged per step, ISI ¼ 1 s in all cases) superimposed on the constant background.
For single-flash responses, the amplitude and latency of the major ERG
components (a- and b-waves for dark-adapted, b-wave only for light-adapted) was
measured (Espion software; Diagnosys LLC) using automated and manual
methods. By convention, b-wave amplitude is measured from the a-wave trough
(where present) and a-wave amplitude is measured from baseline to a-wave trough.
Implicit times of both waveforms was measured from stimulus onset to the peak
amplitude.
Unfiltered traces were used for dark-adapted responses whereas in light-adapted
records both a band-pass filter (between 0.625 and 300Hz) and a 50Hz notch filter
were applied.
For flicker responses the ERG waveform becomes sinusoidal at higher stimulus
frequencies (ie, 45Hz) and discreet a- and b-waves are not distinguishable. Thus
the peak-to-peak amplitude of the waveform following the first stimuli of the sweep
was measured instead and the delay until the first positive deflection was also
quantified to estimate response timing. These records were band-pass filtered
between 0.625 and 300Hz and a 50Hz notch filter was also applied. In all cases,
values were obtained for records from both eyes of each animal and then a mean
value was calculated per individual to be used in statistical analysis.
DAB immunolabelling. Mice were euthanized, heads removed, skinned and
bisected along the midline before fixation in 10% neutral buffered formalin
(Surgipath). Fixed specimens were decalcified, dehydrated and embedded in
paraffin wax. For immunohistochemistry, 5 mm sagittal sections were mounted on
charged slides. Slides were dewaxed, incubated with 3% hydrogen peroxide,
and antigen retrieval performed using 10mM citrate buffer. Sections were then
incubated with an anti-Slc4a10 antibody (1:200, sc-161917) for one hour at room
temperature. Control sections were incubated with primary antibody that had been
incubated with the immunizing peptide. Sections were rinsed, and incubated with a
biotinylated rabbit anti-goat secondary antibody (1:400, DAKO), rinsed again,
incubated with Streptavidin-peroxidase complex (VECTASTAIN elite ABC kit,
Vector Laboratories), and rinsed again. A peroxide-based immunohistochemical
method utilising diaminobenzidine (DAB) was used to detect staining. The DAB
solution (DAKO) was added to the sections. Once the brown stain became visible
slides were washed with PBS. Sections were counterstained with haematoxylin,
cleared and mounted
Endocochlear potential measurements. These were performed as previously
described by Teubner et al40. Briefly, mice were intraperitonealy anaesthetised with
sodium thiobutabarbital (0.1mg g 1 bodyweight) (Inactin, Sigma, Deisenhofen,
Germany). The cochleae were exposed by a ventral approach and access to the
basal scala media gained by thinning the bone over the SL. Borosilicate capillaries
filled with 0.5M NaCl were used as glass electrodes connected to a FD223 (World
Precision Instruments) differential electrometer, which was used to measure the
endocochlear potential.
Data availability. All raw data and automatically annotated phenotype data
and SNVs are available via the publically accessible data portal MouseBook (http://
www.mousebook.org/), and metadata can be found at http://www.mousephenotype.
org/harwellageingscreen. The Whole Genome Sequencing data has been deposited to
the NCBI Short Read Archive database (https://www.ncbi.nlm.nih.gov/Traces/sra/
sra.cgi?) under accession number PRJNA322401. Individual SRA biosample IDs are
as follows; G1-C57BL/6J-C3H.pde6þ mice; MPC-81, SAMN05172945; MPC-91,
SAMN05172946; MPC-96, SAMN05172947; MPC-102, SAMN05172945; MPC-107,
SAMN05177793; MPC-173, SAMN05188717; MPC-178, SAMN05188718;
MPC-184, SAMN05188720; MPC-185, SAMN05188721; MPC-187,
SAMN05193605; MPC-191, SAMN05193608; MPC-200, SAMN05178551;
MPC-201, SAMN05178552; MPC-203, SAMN05178554; MPC-205,
SAMN05178563; MPC-214, SAMN05178564; MPC-225, SAMN05178565;
MPC-227, SAMN05178566; MPC-231, SAMN05178611; MPC-232,
SAMN05178612; MPC-234, SAMN05179116; MPC-236, SAMN05179117;
MPC-242, SAMN05179118; MPC-246, SAMN05179119; MPC-264,
SAMN05208809; MPC-265, SAMN05185998; MPC-267, SAMN05185999;
MPC-269, SAMN05186000; MPC-276, SAMN05186001; MPC-282,
SAMN05186002; MPC-285, SAMN05186003; MPC-290, SAMN05188407;
MPC-291, SAMN05188408; MPC-292, SAMN05188409, MPC-294,
SAMN05188410, and for G3-C57BL/6J-C3H.pde6þ mice; MPC-125,
SAMN05177794; MPC-151, SAMN05177795; MPC-169, SAMN05188716;
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MPC-188, SAMN05193606; MPC-190, SAMN05193607; MPC-202,
SAMN05178553.
References
1. Niccoli, T. & Partridge, L. Ageing as a risk factor for disease. Curr. Biol. 22,
R741–R752 (2012).
2. Nolan, P. M. et al. A systematic, genome-wide, phenotype-driven mutagenesis
programme for gene function studies in the mouse. Nat. Genet. 25, 440–443
(2000).
3. Hrabe de Angelis, M. H. et al. Genome-wide, large-scale production of mutant
mice by ENU mutagenesis. Nat. Genet. 25, 444–447 (2000).
4. Acevedo-Arozena, A. et al. ENU mutagenesis, a way forward to understand
gene function. Annu. Rev. Genomics Hum. Genet. 9, 49–69 (2008).
5. Bull, K. R. et al. Unlocking the bottleneck in forward genetics using whole-
genome sequencing and identity by descent to isolate causative mutations. PLoS
Genet. 9, e1003219 (2013).
6. Wang, T. et al. Real-time resolution of point mutations that cause
phenovariance in mice. Proc. Natl Acad. Sci. USA 112, E440–E449 (2015).
7. Cook, M. C., Vinuesa, C. G. & Goodnow, C. C. ENU-mutagenesis: insight into
immune function and pathology. Curr. Opin. Immunol. 18, 627–633 (2006).
8. Hoebe, K. & Beutler, B. Forward genetic analysis of TLR-signaling pathways: an
evaluation. Adv. Drug Deliv. Rev. 60, 824–829 (2008).
9. Wallace, D. C. Mitochondrial DNA mutations in disease and aging. Environ.
Mol. Mutagen 51, 440–450 (2010).
10. Burton, D. G. & Krizhanovsky, V. Physiological and pathological consequences
of cellular senescence. Cell. Mol. Life Sci. 71, 4373–4386 (2014).
11. Hoelter, S. M. et al. ‘Sighted C3H’ mice--a tool for analysing the influence of
vision on mouse behaviour? Front. Biosci. 13, 5810–5823 (2008).
12. Johnson, K. R., Zheng, Q. Y. & Noben-Trauth, K. Strain background effects and
genetic modifiers of hearing in mice. Brain Res. 1091, 79–88 (2006).
13. Brown, S. D. & Moore, M. W. The International Mouse Phenotyping
Consortium: past and future perspectives on mouse phenotyping. Mamm.
Genome 23, 632–640 (2012).
14. Miner, J. H. & Li, C. Defective glomerulogenesis in the absence of laminin
alpha5 demonstrates a developmental role for the kidney glomerular basement
membrane. Dev. Biol. 217, 278–289 (2000).
15. Shannon, M. B., Patton, B. L., Harvey, S. J. & Miner, J. H. A hypomorphic
mutation in the mouse laminin alpha5 gene causes polycystic kidney disease.
J. Am. Soc. Nephrol. 17, 1913–1922 (2006).
16. Chatterjee, R. et al. Targeted exome sequencing integrated with
clinicopathological information reveals novel and rare mutations in atypical,
suspected and unknown cases of Alport syndrome or proteinuria. PLoS ONE 8,
e76360 (2013).
17. Watanabe, H., Nakata, K., Kimata, K., Nakanishi, I. & Yamada, Y. Dwarfism
and age-associated spinal degeneration of heterozygote cmd mice defective in
aggrecan. Proc. Natl Acad. Sci. USA 94, 6943–6947 (1997).
18. Watanabe, H. et al. Mouse cartilage matrix deficiency (cmd) caused by a 7 bp
deletion in the aggrecan gene. Nat. Genet. 7, 154–157 (1994).
19. Gleghorn, L., Ramesar, R., Beighton, P. & Wallis, G. A mutation in the variable
repeat region of the aggrecan gene (AGC1) causes a form of
spondyloepiphyseal dysplasia associated with severe, premature osteoarthritis.
Am. J. Hum. Genet. 77, 484–490 (2005).
20. Stattin, E. L. et al. A missense mutation in the aggrecan C-type lectin domain
disrupts extracellular matrix interactions and causes dominant familial
osteochondritis dissecans. Am. J. Hum. Genet. 86, 126–137 (2010).
21. Voros, G., Sandy, J. D., Collen, D. & Lijnen, H. R. Expression of aggrecan(ases)
during murine preadipocyte differentiation and adipose tissue development.
Biochim. Biophys. Acta 1760, 1837–1844 (2006).
22. Adzhubei, I. A. et al. A method and server for predicting damaging missense
mutations. Nat. Methods 7, 248–249 (2010).
23. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat.
Protoc. 4, 1073–1081 (2009).
24. Schwarz, J. M., Rodelsperger, C., Schuelke, M. & Seelow, D. MutationTaster
evaluates disease-causing potential of sequence alterations. Nat. Methods 7,
575–576 (2010).
25. Hilgen, G. et al. Lack of the sodium-driven chloride bicarbonate exchanger
NCBE impairs visual function in the mouse retina. PLoS ONE 7, e46155 (2012).
26. Jacobs, S. et al. Mice with targeted Slc4a10 gene disruption have small brain
ventricles and show reduced neuronal excitability. Proc. Natl Acad. Sci. USA
105, 311–316 (2008).
27. Bok, D. et al. Blindness and auditory impairment caused by loss of the sodium
bicarbonate cotransporter NBC3. Nat. Genet. 34, 313–319 (2003).
28. Schuknecht, H. F. Presbycusis. Laryngoscope 65, 402–419 (1955).
29. Schuknecht, H. F. & Gacek, M. R. Cochlear pathology in presbycusis. Ann. Otol.
Rhinol. Laryngol. 102, 1–16 (1993).
30. Ohlemiller, K. K. Age-related hearing loss: the status of Schuknecht’s typology.
Curr. Opin. Otolaryngol. Head Neck Surg. 12, 439–443 (2004).
31. Goronzy, J. J. & Weyand, C. M. Understanding immunosenescence to improve
responses to vaccines. Nat. Immunol. 14, 428–436 (2013).
32. Dykens, J. A. & Will, Y. The significance of mitochondrial toxicity testing in
drug development. Drug Discov Today 12, 777–785 (2007).
33. Kane, K. L. et al. Genetic background effects on age-related hearing loss
associated with Cdh23 variants in mice. Hear. Res. 283, 80–88 (2012).
34. Li, H. & Durbin, R. Fast and accurate short read alignment with
Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
35. Keane, T. M. et al. Mouse genomic variation and its effect on phenotypes and
gene regulation. Nature 477, 289–294 (2011).
36. Grant, J. R., Arantes, A. S., Liao, X. & Stothard, P. In-depth annotation of
SNPs arising from resequencing projects using NGS-SNP. Bioinformatics 27,
2300–2301 (2011).
37. Solberg, H. E. The theory of reference values Part 5. Statistical treatment of
collected reference values. Determination of reference limits. J. Clin. Chem.
Clin. Biochem. 21, 749–760 (1983).
38. Hunter-Duvar, I. M. A technique for preparation of cochlear specimens for
assessment with the scanning electron microscope. Acta Otolaryngol. Suppl.
351, 3–23 (1978).
39. Lipinski, D. M. et al. Vesicular stomatitis virus glycoprotein- and Venezuelan
equine encephalitis virus-derived glycoprotein-pseudotyped lentivirus vectors
differentially transduce corneal endothelium, trabecular meshwork, and human
photoreceptors. Hum. Gene Ther. 25, 50–62 (2014).
40. Teubner, B. et al. Connexin30 (Gjb6)-deficiency causes severe hearing
impairment and lack of endocochlear potential. Hum. Mol. Genet. 12, 13–21
(2003).
Acknowledgements
This work was funded by the Medical Research Council, UK, (primarily by reference MC
U142684172 and partly by MC U142661184, MC U142684173, MC U142684175 and
MC_PC_U127561112). The work was also partly funded by Arthritis Research UK
Centre for Osteoarthritis Pathogenesis (A.B., T.V.), grant reference 20205, the BBSRC
(S.N.P.), the EC—TREATRUSH (Health-F2-2010-242013), ERC advanced grant
‘Hair bundle’ (ERC-2011-AdG 294570), and a Wellcome Trust Strategic Award
(098461/Z/12/Z) to the Sleep and Circadian Neuroscience Institute (SCNi) (R.G.F. and
S.N.P.). We thank the High-Throughput Genomics Group at the Wellcome Trust Centre
for Human Genetics (funded by Wellcome Trust, grant reference 090532/Z/09/Z and
MRC Hub grant G0900747 91070) for the generation of the sequencing data.
Author contributions
P.K.P. and S.D.M.B. conceived the study and directed the research. P.K.P., M.R.B. and
S.D.M.B. wrote the manuscript. M.R.B. and S.D.M.B. directed the research into the
trombone (Slc4a10L647P) mutant. P.K.P., M.R.B., P.J., L.W., A.B., M.E.G., V.M., A.B.,
C.A., T.A., G.B., L.C., J.D., S.F., L.G., S.H., A.H., I.H., R.H., T.H., A.H., M.H., R.K.,
H.V.D., G.L., R.M., S.M., T.N., A.P., K.P., B.S., F.S., M.C., S.H.C., R.G.F., I.J.J., S.N.P.,
R.V.T., T.V., C.S., S.W., A.E.-A., C.P., A.A.-A., P.M.N. and R.C. undertook mouse
generation, phenotyping and, data acquisition and assessment from the phenotyping
pipelines. M.S., S.G., A.B., S.K., S.S., and A.-M.M., developed data tools and databases
and carried out data and statistical analyses.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing financial interests: The authors declare no competing financial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Potter, P. K. et al. Novel gene function revealed by mouse
mutagenesis screens for models of age-related disease. Nat. Commun. 7:12444
doi: 10.1038/ncomms12444 (2016).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2016
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12444 ARTICLE
NATURE COMMUNICATIONS | 7:12444 | DOI: 10.1038/ncomms12444 |www.nature.com/naturecommunications 13
